Goldseeker, there is something important you purposely are neglecting to mention to anyone who even believes your tales of whoa (like misleading investors on the license with Abbott which IS intact, and today trying to say that Goshen scientists intentionally left out early stage cancers again a false statement, and the saliva test had only 90% sensitivity which Dr Moro said HE can get it very close to 100%). This a test for ALL CANCERS number one. Number two, it is a screening tool and would be followed up with a serum recaf. I am bored and don't feel like reviewing all of the other multitude of uses for recaf, but the bottom line is that recaf is not comparable to any other marker to date. There are no comparisons.
This marker has one by one been fulfilling every requirement for a viable, commercializable technology. Just because YOU don't want it, or to see our company or Dr Moro succeed, that's not how the world works. As a shareholder, I am looking forward to what is next. The doors have been opening for Biocurex and next week will be another milestone.
News 
Market Data 
Discover 
AI
